‘Providing evidence-centered answers to clinically relevant queries is not easy when it comes to rare diseases. Huge collaborative efforts are pivotal not merely for understanding natural background of rare diseases, but also in advancing therapies,’ said Dr. Brendan Lee, Robert and Janice McNair Endowed Seat of Molecular and Individual Genetics and the main investigator for the Brittle Bone Disorders Consortium.. Cesarean delivery does not reduce fracture risk in newborns with uncommon bone disorder Cesarean delivery was not connected with reduction in the at-birth fracture prices in infants with osteogenesis imperfecta, a rare bone disorder, said a consortium of researchers led by Baylor College of Medicine.Regarding the the applicant selection, AstraZeneca can pay Regulus $2.5 million and will assume advancement of the scheduled plan following acceptance of an Investigational New Medication app. In the near term, Regulus and AstraZeneca intend to submit essential preclinical data on the RG-125 plan to be offered at a scientific conference later this season and be prepared to initiate a Stage I research of RG-125 in human beings by the finish of 2015. Gibson, Ph.D., Chief Scientific Officer of Regulus. The role of miR-103/107 in insulin sensitivity and resistance was acknowledged by the laboratory of Dr first.